多发性骨髓瘤治疗的最新进展增加了对该疾病的准确诊断的需求。骨骼和骨髓病变的检测在多发性骨髓瘤的研究中至关重要,并且通常决定开始治疗的决定。此外,微小残留病的检测对于预后判断和治疗计划很重要,它强调了对准确评估患者对多发性骨髓瘤治疗反应的灵敏成像方法的需求。低剂量全身CT与常规骨骼检查相比,在检测骨骼疾病方面具有更高的敏感性,这可以揭示导致治疗和疾病管理变化的信息,这些信息可以预防或延迟由于骨骼相关事件而导致的临床重大发病率和死亡率的发生。鉴于可用于检测骨骼和骨髓病变的多种选择,从常规骨骼测量到全身CT,PET/CT,MRI,国际骨髓瘤工作组决定制定关于在不同疾病阶段最佳使用成像方法的指南.这些关于临床试验内外成像的建议将有助于全球单克隆浆细胞疾病的标准化成像,以比较结果和统一多发性骨髓瘤的治疗方法。
Recent advances in the treatment of multiple myeloma have increased the need for accurate diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the investigation of multiple myeloma and often dictates the decision to start treatment. Furthermore, detection of minimal residual disease is important for prognosis determination and treatment planning, and it has underscored an unmet need for sensitive imaging methods that accurately assess patient response to multiple myeloma treatment. Low-dose whole-body CT has increased sensitivity compared with conventional skeletal survey in the detection of bone disease, which can reveal information leading to changes in therapy and disease management that could prevent or delay the onset of clinically significant morbidity and mortality as a result of skeletal-related events. Given the multiple options available for the detection of bone and bone marrow lesions, ranging from conventional skeletal survey to whole-body CT, PET/CT, and MRI, the International Myeloma Working Group decided to establish
guidelines on optimal use of imaging methods at different disease stages. These recommendations on imaging within and outside of clinical trials will help standardise imaging for monoclonal plasma cell disorders worldwide to allow the comparison of results and the unification of treatment approaches for multiple myeloma.